SignalHF vs Reveal LINQ Insertable Cardiac Monitor

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
by Implicity
VS
by Medtronic

AI Verdict

SignalHF by Implicity is an AI algorithm that predicts heart failure hospitalizations by analyzing data from various cardiac implantable electronic devices. In contrast, the Medtronic Reveal LINQ Insertable Cardiac Monitor is an implantable device that uses AI to improve the accuracy of its own long-term ECG monitoring for conditions like atrial fibrillation and syncope. While both utilize AI in cardiology, SignalHF provides predictive analytics for heart failure based on existing device data, whereas the Reveal LINQ ICM is a primary diagnostic tool focused on enhancing the quality of its collected cardiac rhythm data.

Choose SignalHF if…

Choose SignalHF if your primary objective is to proactively prevent heart failure hospitalizations in patients already equipped with various cardiac implantable electronic devices (CIEDs). This FDA-cleared AI algorithm excels at analyzing existing CIED data to predict 30-day hospitalization risk, enabling timely clinical intervention and personalized care plans for at-risk individuals.

View SignalHF →

Choose Reveal LINQ if…

Choose the Reveal LINQ Insertable Cardiac Monitor if you require long-term, highly accurate diagnostic monitoring for patients experiencing infrequent or undiagnosed cardiac symptoms like syncope or suspected atrial fibrillation. Its deep learning AccuRhythm™ AI algorithms significantly reduce false alerts, improving diagnostic yield and providing continuous subcutaneous ECG data over an extended period for definitive diagnosis.

View Reveal LINQ →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature SignalHF Reveal LINQ
Pricing Contact for pricing Contact vendor
Deployment SaaS The Reveal LINQ ICM is an implantable device placed just beneath the skin in the upper left side of the chest through a small incision. The system includes a MyCareLink™ Monitor, a bedside unit that collects data from the ICM and sends it to the doctor. The Reveal LINQ Mobile Manager app, used by healthcare professionals, is downloaded to an iPad or Android tablet and paired via Bluetooth to a Medtronic patient connector, which communicates with the ICMs.
BAA Available Yes AI-estimated Yes AI-estimated
FDA Status Cleared AI-estimated Cleared AI-estimated
HIPAA Yes AI-estimated Unknown

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Reveal LINQ

Tool B's AccuRhythmu2122 AI algorithms significantly reduce false alerts for conditions like AF and Pause, directly improving clinician usability by providing cleaner, more reliable data and reducing alert fatigue. While Tool A offers AI-driven alert management, the fundamental improvement in data quality from Tool B's AI is a stronger usability enhancement for clinicians interpreting device data.

Clinical Value

SignalHF

Tool A offers significant clinical value by predicting heart failure hospitalizations within 30 days, enabling early intervention and personalized care. This proactive approach to preventing a major adverse event provides a direct and measurable impact on patient outcomes. Tool B focuses on enhancing diagnostic yield for arrhythmias, which is also valuable but less directly preventative of an acute event.

Pricing & Value

Tie

Both tools explicitly state that pricing information requires direct contact with the vendor and is not publicly disclosed. Without any pricing details, it is impossible to conduct a head-to-head comparison of their value propositions based on cost.

Enterprise Readiness

SignalHF

Tool A demonstrates stronger enterprise readiness due to its manufacturer-agnostic compatibility with various cardiac implantable electronic devices (CIEDs). This feature is crucial for healthcare enterprises that manage diverse device populations, simplifying data centralization and integration across different vendors.

Innovation

SignalHF

Tool A's FDA-cleared AI algorithm for predicting heart failure hospitalizations within 30 days represents a more innovative and paradigm-shifting application of AI in healthcare, moving towards proactive and preventative care. While Tool B's AI for reducing false alerts is innovative in refining diagnostic accuracy, Tool A's predictive capability for a major clinical event is a more novel advancement.

Support & Docs

Reveal LINQ

Medtronic (Tool B) provides a comprehensive support ecosystem, including dedicated phone support services for patients, extensive clinician manuals, patient education materials, and specialized monitoring and triaging services for healthcare professionals. This robust infrastructure, typical of a large medical device company, suggests a more developed and accessible support system compared to the information available for Tool A.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature SignalHF Reveal LINQ
Name SignalHF Reveal LINQ Insertable Cardiac Monitor
Company Implicity Medtronic
Description FDA-cleared AI algorithm that predicts heart failure hospitalizations within 30 days by analyzing data from various cardiac implantable electronic devices, enabling early intervention and personalized care. The Medtronic LINQ IIu2122 Insertable Cardiac Monitor (ICM) with AccuRhythmu2122 AI algorithms provides long-term, accurate heart monitoring by using deep learning AI to reduce false alerts and enhance diagnostic yield for conditions like atrial fibrillation and syncope.
Tagline Revolutionizing Heart Failure Care with Predictive AI Accuracy matters.
Key Features FDA-cleared AI algorithm for heart failure prediction, Predicts heart failure hospitalizations within 30 days, Manufacturer-agnostic compatibility with various CIEDs (pacemakers, ICDs, CRTs), Analyzes physiological data, demographics, lead measurements, episodes, and therapies, Generates automatic alerts for care teams based on risk scores, Enables early intervention and personalized care plans, Unified platform for centralizing cardiac implantable device data, AI-driven alert management to filter and highlight relevant events AccuRhythmu2122 AI algorithms for reduced false alerts (AF and Pause), 4.5-year battery longevity (nominal settings), Continuous, long-term subcutaneous ECG monitoring, Remote programming capabilities, Enhanced ECG experience for clinical adjudication, MyCareLink Heartu2122 mobile app for patient data transmission, MyCareLink Relayu2122 home communicator for data transmission, MRI compatible (at u2264 3T with no post-insertion waiting)

Videos

Demos, reviews, and walkthroughs featuring SignalHF and Reveal LINQ.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

SignalHF by Implicity is designed to predict heart failure hospitalizations within 30 days by analyzing data from existing cardiac implantable electronic devices (CIEDs), enabling early intervention and personalized care. The Medtronic Reveal LINQ Insertable Cardiac Monitor (ICM) is for long-term, accurate heart monitoring, using AI to reduce false alerts and enhance diagnostic yield for conditions such as atrial fibrillation and syncope.
SignalHF uses an FDA-cleared AI algorithm to analyze various physiological data, demographics, lead measurements, episodes, and therapies from CIEDs to generate automatic alerts for care teams based on heart failure risk scores. The Reveal LINQ ICM incorporates AccuRhythmu2122 AI algorithms that apply deep learning to reduce false alerts for atrial fibrillation and pauses, thereby enhancing diagnostic accuracy and providing an enhanced ECG experience for clinical adjudication.
SignalHF offers manufacturer-agnostic compatibility, analyzing data from various existing cardiac implantable electronic devices (CIEDs) like pacemakers, ICDs, and CRTs. The Reveal LINQ ICM is an implantable device itself, providing continuous, long-term subcutaneous ECG monitoring.
Yes, SignalHF features AI-driven alert management to filter and highlight relevant events, aiming to reduce alert fatigue related to heart failure prediction. The Reveal LINQ ICM utilizes AccuRhythmu2122 AI algorithms specifically to reduce false alerts for atrial fibrillation and pauses, improving the relevance of diagnostic findings.
As a SaaS platform, battery longevity is not applicable to the SignalHF software itself, but rather to the CIEDs it monitors. The Reveal LINQ ICM, being an implantable device, has a 4.5-year battery longevity (nominal settings).

Backers

Who funded each tool's parent company.

SignalHF

AI Tool Finder
AI-powered search. Results may not be comprehensive.